Saturday 17 October 2026 Export AYTU’s income statement to Excel — free account

Aytu BioPharma, Inc.

AYTU Healthcare Drug Manufacturers Specialty & Generic

Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.

2.04 0.03 +1.49%

Follow AYTU

Alert me

Market cap: $21.8M
P/E: 0.0×
Fwd P/E: −9.2×
Dividend yield: —
F-score: 3/9
Altman Z: −4.04
Beneish M: −3.48
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.16%

Capital & Financial Ratios $m

Market Cap 21.84

Revenue 57.57

Net Income (14.25)

Free Cash Flow 3.24

Net Debt (9.28)

Current Ratio 1.13

Debt/Equity 0.48

P/E ratio 0.00

Fwd P/E (9.18)

P/S ratio 0.44

P/B ratio 0.71

Past 5Y EPS Growth —

This Y EPS Growth 46.26%

Next Y EPS Growth 143.32%

Next Y revenue growth 17.96%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 44.75%

10-year low 10-year high

P/B against its own 10 years 62.18%

10-year low 10-year high

EV/Sales against its own 10 years 41.03%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	23	20	31	26
Receivables	29	24	31	23
Inventory	12	12	11	7
Other	—	—	—	—
	71	62	79	62

	2023	2024	2025	2026
Payables	13	10	11	11
ST’ Debt	2	4	11	8
Other	7	9	3	0
	69	62	63	55

Compound Annual Growth %

	10y	5y	3y
Sales	36.51%	(2.59%)	(18.77%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	13.34%	(23.83%)	(3.59%)

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	14	15	12	16	58
’25	17	16	18	15	66
’24	18	19	14	15	65
’23	28	26	23	31	107
’22	22	23	24	27	97
’21	14	15	13	23	66

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(1)	4	(4)	4	3
’25	(1)	3	(6)	3	(2)
’24	0	0	0	(1)	(1)
’23	(9)	(2)	(3)	9	(5)
’22	(4)	(9)	(9)	(7)	(29)
’21	(8)	(3)	(9)	(6)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(1)	4	(4)	4	3
’25	(1)	3	(7)	3	(1)
’24	0	0	0	(1)	(2)
’23	(9)	(2)	(3)	9	(5)
’22	(4)	(9)	(9)	(7)	(29)
’21	(8)	(3)	(9)	(9)	(28)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0.10	(1.05)	(0.53)	0.00	(1.16)
’25	—	(0.26)	0.21	(2.92)	(2.16)
’24	(1.48)	(0.04)	(0.52)	(0.82)	(2.86)
’23	(0.28)	(2.15)	(1.93)	(0.59)	(5.11)
’22	(21.80)	(8.80)	(35.80)	(9.80)	(75.00)
’21	(8.00)	(14.40)	(28.20)	(20.04)	(69.60)

Fiscal quarters ending in the months shown.

value withheld pending a data check

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	8,200.00	136.00	130.00	68.00	26.40	3.00	1.38	1.30	0.95	1.89	Analyst estimates 2027–2029 Powerpack
	High	100,800.00	17,040.00	522.00	598.00	235.20	31.80	4.40	3.45	2.82	3.07
People
People	Employees	63	57	53	75	175	164	150	102	83	76
	Revenue/emp, $m	0.05	0.06	0.14	0.37	0.38	0.59	0.72	0.64	0.80	0.76
Income, $m
Income, $m	Revenue	3	4	7	28	66	97	107	65	66	58
	Gross margin, %	56.00	43.98	69.92	70.03	44.49	54.08	62.04	75.26	69.04	63.95
	EBT	(23)	(10)	(27)	(14)	(58)	(109)	(17)	(10)	(14)	(14)
	EBT margin, %	(698.67)	(278.35)	(370.63)	(49.29)	(88.42)	(112.64)	(15.88)	(15.92)	(20.71)	(24.72)
	Net income	(23)	(10)	(27)	(14)	(58)	(109)	(17)	(16)	(14)	(14)
	Depreciation	5	3	3	6	22	85	9	7	5	4
Per share, $
Per share, $	Revenue	1,400.70	1,109.12	187.70	122.27	78.38	65.76	32.16	11.77	10.57	4.67
	Earnings	(9,659.72)	(3,062.00)	(696.00)	(60.28)	(69.60)	(75.00)	(5.11)	(2.86)	(2.16)	(1.16)
	Cash flow	(6,012.91)	(4,830.39)	(354.65)	(125.55)	(31.01)	(19.61)	(1.54)	(0.25)	(0.31)	0.27
	Capex	(48.52)	(143.85)	(14.35)	(25.88)	(2.80)	0.00	0.00	(0.06)	0.07	0.00
	Free cash flow	(6,061.43)	(4,974.24)	(369.01)	(151.43)	(33.80)	(19.61)	(1.54)	(0.31)	(0.24)	0.26
	Book value	1,739.04	4,068.03	181.74	420.42	164.28	30.14	11.78	5.00	3.02	2.86
	Shares, m	0	0	0	0	1	1	3	6	6	12
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	33.70	0.94	2.05	2.32	1.28	0.21	0.05	0.24	0.21	0.46
	P/B	27.14	0.26	2.11	0.68	0.61	0.46	0.14	0.57	0.72	0.75
	EV/Sales	33.43	(1.00)	1.20	1.10	0.90	0.20	(0.01)	0.17	0.07	0.30
	EV/FCF	(7.72)	0.22	(0.61)	(0.76)	(1.47)	(0.45)	0.07	(0.97)	(3.04)	5.32
Cash, $m
Cash, $m	Operating cash flow	(14)	(16)	(14)	(28)	(26)	(29)	(5)	(1)	(2)	3
	Capex	0	0	(1)	(6)	(2)	—	—	0	0	0
	Free cash flow	(14)	(16)	(14)	(34)	(28)	(29)	(5)	(2)	(1)	3
Balance, $m
Balance, $m	Working capital	(1)	6	10	47	(4)	(5)	2	0	16	7
	Total debt	—	—	—	14	25	18	16	15	22	17
	Net debt	(1)	(7)	(11)	(34)	(25)	(1)	(7)	(5)	(9)	(9)
	Shareholders’ equity	4	13	7	95	138	44	39	28	19	35
Returns, %
Returns, %	ROA	(114.43)	(56.51)	(97.28)	(14.49)	(27.83)	(53.95)	(12.44)	(12.45)	(11.20)	(12.44)
	ROIC	(402.85)	(195.07)	0.00	(21.59)	(32.72)	(159.24)	(32.58)	(4.35)	(49.77)	(19.99)
	ROE	(319.60)	(116.94)	(264.55)	(26.68)	(50.12)	(119.62)	(40.76)	(47.24)	(58.10)	(52.55)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IXHL Incannex Healthcare Inc.	$36.1M	— (loss-making)	— (loss-making)	−92.31% (below 0%: shrinking)	n/m	+327.73% (above 0%: growing)	100.00%	0.00%	Compare
RMTI Rockwell Medical, Inc.	$32.2M	— (loss-making)	— (loss-making)	+10.63% (above 0%: growing)	n/m	−12.92% (below 0%: shrinking)	18.24%	(5.97%)	Compare
CPHI China Pharma Holdings, Inc.	$31.3M	— (loss-making)	— (loss-making)	−7.56% (below 0%: shrinking)	n/m	−113.57% (below 0%: shrinking)	8.82%	(150.99%)	Compare
SHPH Shuttle Pharmaceuticals Holdings, Inc.	$26.5M	0.2×	—	—	n/m	+82.01% (above 0%: growing)	0.00%	0.00%	Compare
TXMD TherapeuticsMD, Inc.	$22.3M	— (loss-making)	18.9×	−8.72% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+104.46% (above 0%: growing)	100.00%	(93.90%)	Compare
AYTU Aytu BioPharma, Inc.	$21.8M	— (loss-making)	— (loss-making)	+6.42% (above 0%: growing)	n/m	+57.72% (above 0%: growing)	64.63%	(4.82%)
UPC Universe Pharmaceuticals INC	$20.9M	— (loss-making)	4.1×	−23.98% (below 0%: shrinking)	−110.15% (below 0%: shrinking)	−84.99% (below 0%: shrinking)	32.57%	0.00%	Compare
BGXXQ Bright Green Corporation	$13.9M	— (loss-making)	—	—	n/m	−1.46% (below 0%: shrinking)	0.00%	0.00%	Compare
BFRI Biofrontera Inc.	$12.6M	— (loss-making)	— (loss-making)	+32.92% (above 0%: growing)	n/m	+45.57% (above 0%: growing)	79.92%	(4.37%)	Compare
Median of peers	$24.4M	—	—	−8.14%	—	+22.06%	25.41%	(2.18%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Aytu BioPharma, Inc. (AYTU) key facts

Concern: Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
Aytu BioPharma, Inc. (AYTU) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AYTU traded at $2.04, a market capitalization of $21.8 million.
Return on equity was −52.6% and debt-to-equity 0.48.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.04 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 2, 2026.